Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer

• Verfasst von: Stieglmaier, Julia [VerfasserIn]
• Verfasst von: Benjamin, Jonathan [VerfasserIn]
• Verfasst von: Nagorsen, Dirk [VerfasserIn]
• Titel: Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
• Verf.angabe: Julia Stieglmaier, Jonathan Benjamin and Dirk Nagorsen
• E-Jahr: 2015
• Jahr: 13 May 2015
• Umfang: 7 S.
• Fussnoten: Gesehen am 07.01.2019
• Titel Quelle: Enthalten in: Expert opinion on biological therapy
• Ort Quelle: Abingdon : Taylor & Francis Group, 2001
• Jahr Quelle: 2015
• Band/Heft Quelle: 15(2015), 8, Seite 1093-1099
• ISSN Quelle: 1744-7682
• DOI: doi:10.1517/14712598.2015.1041373
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bispecific antibody
• Sach-SW: BiTE®
• Sach-SW: blinatumomab
• Sach-SW: cancer immunotherapy
• Sach-SW: T-cells
• K10plus-PPN: 1585967335

Abstract

Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE® (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal binding domains of monoclonal antibodies for tumor-associated surface antigens and for the T-cell receptor-associated molecule CD3. Concurrent engagement of the target cell antigen and CD3 leads to activation of polyclonal cytotoxic T-cells, resulting in target cell lysis. Blinatumomab, a BiTE targeting CD19, is being investigated in a broad range of B-cell malignancies and has recently been approved in the USA by the US FDA for Philadelphia chromosome-negative relapsed/refractory B-acute lymphoblastic leukemia under the trade name BLINCYTO™. The BiTE platform is one of the clinically most advanced T-cell immunotherapy options.